Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04429815

Acronym

MAGIC

Enrollment

195

Registered

2020-06-12

Start date

2020-08-25

Completion date

2021-05-26

Last updated

2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Behaviors

Brief summary

Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus. The objectives are : * To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers. * To show that active smokers are less infected with COVID-19 than non-smokers. * To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.

Interventions

DIAGNOSTIC_TESTSerological test for COVID-19.

Serological test for COVID-19 performed as part of standard of care.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years old * Subject who will require a serological test for COVID-19 virus as part of standard of care. * Group 1: Active smoker since October 2019 * Group 2: Smoker undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019 * Group 3: Non-smoker

Exclusion criteria

* Inpatient subject * Subjects with a chronic serious pathology modifying the risk of exposure to COVID-19

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with a positive serological test for COVID-19.	1 day	Percentage of patients with a positive serological test for COVID-19.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026